Probation draws to a close for Bristol-Myers
Bristol-Myers Squibb is finally getting off probation with the end of its two-year deferred prosecution period today. "Bristol-Myers Squibb has made significant and transformational changes in its compliance practices as a result of the DPA [deferred prosecution agreement," said U.S. attorney Christopher J. Christie. The company agreed to stick to the letter of the law back in 2005 in order to escape prosecution for an illegal scheme known as channel stuffing.
- check out the statement from BMS
- read the MarketWatch report
ALSO: Bristol-Myers announced that its drug Orencia may be effective as a therapy against arthritis in children. Orencia is approved for adults. Report
Related Articles:
BMS board fires Dolan, general counsel. Report
Cornelius get big payday for BMS temp job. Report
FBI agents raid BMS office in deal probe. Report
Better times ahead for BMS? Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
